Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BTYNB (MDK6620) is an inhibitor of the oncofetal mRNA-binding protein IMP1 (IC50 = 5 μM for IMP1 binding to c-Myc mRNA). MDK6620 downregulates β-TrCP1 mRNA and reduces activation of nuclear transcriptional factors-kappa B (NF-κB). It disrupts this enhancer function by impairing IGF2 mRNA-binding protein 1 (IGF2BP1)-RNA association
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 40.00 | |
10 mg | In stock | $ 57.00 | |
25 mg | In stock | $ 94.00 | |
50 mg | In stock | $ 138.00 | |
100 mg | In stock | $ 209.00 | |
200 mg | In stock | $ 325.00 | |
500 mg | In stock | $ 593.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 46.00 |
Description | BTYNB (MDK6620) is an inhibitor of the oncofetal mRNA-binding protein IMP1 (IC50 = 5 μM for IMP1 binding to c-Myc mRNA). MDK6620 downregulates β-TrCP1 mRNA and reduces activation of nuclear transcriptional factors-kappa B (NF-κB). It disrupts this enhancer function by impairing IGF2 mRNA-binding protein 1 (IGF2BP1)-RNA association |
Targets&IC50 | IMP1 c-Myc mRNA internation:5 μM (IC50) |
In vitro | In cells, BTYNB downregulates several mRNA transcripts regulated by IMP1.?BTYNB destabilizes c-Myc mRNA, resulting in downregulation of c-Myc mRNA and protein.?BTYNB downregulates β-TrCP1 mRNA and reduces activation of nuclear transcriptional factors-kappa B (NF-κB).?The oncogenic translation regulator, eEF2, emerged as a new IMP1 target mRNA, enabling BTYNB to inhibit tumor cell protein synthesis.?BTYNB potently inhibited proliferation of IMP1-containing ovarian cancer and melanoma cells with no effect in IMP1-negative cells.?Overexpression of IMP1 reversed BTYNB inhibition of cell proliferation.?BTYNB completely blocked anchorage-independent growth of melanoma and ovarian cancer cells in colony formation assays.?With its ability to target c-Myc and to inhibit proliferation of difficult-to-target melanomas and ovarian cancer cells, and with its unique mode of action, BTYNB is a promising small molecule for further therapeutic evaluation and mechanistic studies[1]. |
Synonyms | MDK6620, BTYNB IMP1 Inhibitor |
Molecular Weight | 309.18 |
Formula | C12H9BrN2OS |
CAS No. | 304456-62-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 62 mg/mL (200.53 mM)
Ethanol: 4 mg/mL (12.94 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BTYNB 304456-62-0 Cell Cycle/Checkpoint NF-Κb Others c-Myc NF-κB Inhibitor inhibit ES-2 IMP1 Myc MDK-6620 IGROV-1 MDK6620 MDK 6620 BTYNB IMP1 Inhibitor cancer cell SK-MEL2 inhibitor